CymaBay Therapeutics, Inc. (CBAY)
CBAY Price and Sentiment
CBAY Latest news
CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary Cholangitis
2021-11-11 08:00Webinar on Monday, November 15th, @ 4:30pm EST Webinar on Monday, November 15th, @ 4:30pm EST
CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2021 Results - Earnings Call Transcript
2021-11-10 21:13CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2021 Results - Earnings Call Transcript
CymaBay Therapeutics Inc. (CBAY) Reports Q3 Loss, Misses Revenue Estimates
2021-11-10 19:05CymaBay Therapeutics Inc. (CBAY) delivered earnings and revenue surprises of -13.79% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2021 Financial Results and Provides Corporate Update
2021-11-10 16:06Over 100 clinical sites now activated in RESPONSE Phase 3 registration study of seladelpar for patients with primary biliary cholangitis (PBC)
CymaBay Therapeutics to Present at Upcoming Investor Conferences
2021-11-04 08:00NEWARK, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual investor conferences including the Credit Suisse 30th Annual Healthcare Conference taking place November 8-11, 2021, the Evercore ISI 4th Annual HealthCONx Conference taking place November 30 – December 2, 2021 and the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place November 30 – December 2, 2021.
CymaBay Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
2021-11-03 16:05NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2021 and to provide a business update.
7 Penny Stocks With the Potential to 10X in 2022
2021-10-29 12:47The broader market looks expensive, but these penny stocks provide low-cost opportunities for considerable upside according to analysts. The post 7 Penny Stocks With the Potential to 10X in 2022 appeared first on InvestorPlace.
CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2021 Results - Earnings Call Transcript
2021-08-12 22:21CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2021 Results - Earnings Call Transcript
CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update
2021-08-12 16:06Secured up to $100 million of additional development funding through a non-dilutive financing transaction with Abingworth
CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021
2021-08-05 16:01NEWARK, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, August 12, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2021 and to provide a business update.